|
Adverse effects. |
||||
| No. of trials |
Chlorpromazine |
Placebo |
RR (95% CI) Random |
|
|
|
||||
| events/total participants |
||||
|
|
||||
| General symptoms |
||||
| Sedation |
18 |
224/725 |
68/517 |
2.30 (1.7–3.1) |
| Weight gain > 10 lb; 4.5 Kg |
5 |
31/75 |
7/90 |
4.44 (2.1–9.3) |
| Extrapyramidal symptoms |
||||
| Acute dystonia |
4 |
28/472 |
5/306 |
3.10 (1.3–7.7) |
| Parkinsonism |
12 |
123/723 |
40/542 |
2.60 (1.2–5.4) |
| Fits |
3 |
19/450 |
4/245 |
2.41 (0.4–16.4) |
| Akathisia |
8 |
53/602 |
40/400 |
0.95 (0.5–1.9) |
| Allergic-type symptoms |
||||
| Agranulocytosis/leucopenia |
7 |
10/207 |
2/187 |
2.02 (0.7–5.6) |
| Rashes/itching |
11 |
42/658 |
21/475 |
1.43 (0.9–2.4) |
| Jaundice |
3 |
8/116 |
1/115 |
4.04 (0.9–17.9) |
| Photosensitivity |
6 |
81/496 |
9/303 |
5.19 (2.7–9.8) |
| Eye opacity |
2 |
97/431 |
16/226 |
3.09 (1.9–5.1) |
| Anti-cholinergic/nor-adrenergic symptoms |
||||
| Hypotension + dizziness |
15 |
113/708 |
38/524 |
1.90 (1.4–2.7) |
| Constipation |
9 |
40/590 |
16/365 |
1.68 (0.9–2.9) |
| Urinary retention |
3 |
11/459 |
5/253 |
1.49 (0.5–4.3) |
| Dry mouth |
5 |
32/473 |
4/283 |
4.00 (1.6–9.8) |
| Blurred vision |
6 |
10/529 |
9/381 |
1.10 (0.5–2.9) |
Adams et al. BMC Medicine 2005 3:15 doi:10.1186/1741-7015-3-15 |
||||